Entellus Medical, Inc. (NASDAQ:ENTL) Director Brian E. Farley sold 3,972 shares of Entellus Medical stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $19.10, for a total value of $75,865.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Brian E. Farley also recently made the following trade(s):

  • On Tuesday, October 3rd, Brian E. Farley sold 6,028 shares of Entellus Medical stock. The stock was sold at an average price of $19.17, for a total value of $115,556.76.

Shares of Entellus Medical, Inc. (NASDAQ:ENTL) traded up 2.82% during midday trading on Wednesday, reaching $20.05. The company’s stock had a trading volume of 219,809 shares. The company’s market capitalization is $508.69 million. Entellus Medical, Inc. has a 12-month low of $12.31 and a 12-month high of $22.57. The company’s 50-day moving average price is $17.67 and its 200 day moving average price is $17.67.

Entellus Medical (NASDAQ:ENTL) last issued its earnings results on Thursday, August 3rd. The medical technology company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.03). The company had revenue of $22.10 million for the quarter, compared to analysts’ expectations of $21.87 million. Entellus Medical had a negative net margin of 41.11% and a negative return on equity of 60.34%. The company’s revenue was up 18.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.27) earnings per share. On average, equities research analysts forecast that Entellus Medical, Inc. will post ($1.61) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This article was reported by American Banking News and is owned by of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/10/04/insider-selling-entellus-medical-inc-entl-director-sells-3972-shares-of-stock.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE lifted its holdings in Entellus Medical by 53.8% in the 1st quarter. Bank of America Corp DE now owns 7,418 shares of the medical technology company’s stock worth $102,000 after buying an additional 2,594 shares during the period. Nationwide Fund Advisors lifted its holdings in Entellus Medical by 61.7% in the 2nd quarter. Nationwide Fund Advisors now owns 6,903 shares of the medical technology company’s stock worth $114,000 after buying an additional 2,635 shares during the period. First Mercantile Trust Co. lifted its holdings in Entellus Medical by 45.3% in the 2nd quarter. First Mercantile Trust Co. now owns 8,206 shares of the medical technology company’s stock worth $136,000 after buying an additional 2,557 shares during the period. Parametric Portfolio Associates LLC lifted its holdings in Entellus Medical by 5.6% in the 1st quarter. Parametric Portfolio Associates LLC now owns 10,888 shares of the medical technology company’s stock worth $150,000 after buying an additional 573 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its holdings in Entellus Medical by 61.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,881 shares of the medical technology company’s stock worth $196,000 after buying an additional 4,533 shares during the period. Institutional investors and hedge funds own 70.24% of the company’s stock.

A number of research firms recently commented on ENTL. BidaskClub lowered Entellus Medical from a “buy” rating to a “hold” rating in a research note on Tuesday, August 1st. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Entellus Medical in a research note on Wednesday, July 12th. Finally, Zacks Investment Research raised Entellus Medical from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $21.83.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Insider Buying and Selling by Quarter for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.